Clinical Trials Browser

INDUSTRY × Breast Neoplasms × trastuzumab biosimilar HLX02 × Clear all

NCT04120246 2024-07-10

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

Phase 1 Suspended

Breast Neoplasms, Neoplasm Metastasis